Literature DB >> 15892431

Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen.

Véronique Bonniaud1, Dianne Jackowski, Bernard Parratte, Rick Paulseth, Sharon Grad, Peter Margetts, Gordon Guyatt.   

Abstract

UNLABELLED: The Qualiveen questionnaire is a urinary disorder (UD)-specific health related quality of life (HRQL) instrument. Recent data suggests Qualiveen has excellent validity in French-speaking multiple sclerosis (MS) patients. AIM: To assess discriminative measurement properties of the English version of Qualiveen.
METHODS: Fifty-five Canadian MS out-patients completed a set of questionnaires, including Qualiveen, MSQOL-54, a MS-specific HRQL questionnaire, urinary function assessments and the Expanded Disability Status Scale (EDSS) twice at an interval of two to four weeks.
RESULTS: Qualiveen proved internally consistent (Cronbach's alpha coefficients 0.73 to 0.90 for the four Qualiveen domains) and test-retest reliable (intraclass correlation coefficients 0.88 to 0.94). Consistent with a priori predictions, we found a strong association between overall Qualiveen score and the degree of incontinence (0.63), a moderate correlation with the type of urinary symptoms (0.49), a weak association with manner of voiding (0.28) and weak or absent correlations with MSQOL-54 domains, EDSS bladder/bowel and global EDSS. Predictions proved generally accurate (weighted kappa = 0.65).
CONCLUSION: The internal consistency, test-retest reliability and cross-sectional construct validity of the English version of Qualiveen are excellent, and similar to the original French version. Further studies should explore Qualiveen's longitudinal validity and responsiveness.

Entities:  

Mesh:

Year:  2005        PMID: 15892431     DOI: 10.1007/s11136-004-0686-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

Review 1.  Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution?

Authors:  J F Kurtzke
Journal:  Neurol Sci       Date:  2000-12       Impact factor: 3.307

Review 2.  Standards for validating health measures: definition and content.

Authors:  J E Ware
Journal:  J Chronic Dis       Date:  1987

Review 3.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

4.  Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction.

Authors:  M W Nortvedt; T Riise; K M Myhr; A M Landtblom; A Bakke; H I Nyland
Journal:  Mult Scler       Date:  2001-08       Impact factor: 6.312

5.  The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing.

Authors:  S Jackson; J Donovan; S Brookes; S Eckford; L Swithinbank; P Abrams
Journal:  Br J Urol       Date:  1996-06

6.  Development of a symptom severity index and a symptom impact index for stress incontinence in women.

Authors:  N Black; J Griffiths; C Pope
Journal:  Neurourol Urodyn       Date:  1996       Impact factor: 2.696

7.  Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen.

Authors:  P Costa; B Perrouin-Verbe; A Colvez; J Didier; P Marquis; A Marrel; G Amarenco; B Espirac; A Leriche
Journal:  Eur Urol       Date:  2001-01       Impact factor: 20.096

8.  A health-related quality of life measure for multiple sclerosis.

Authors:  B G Vickrey; R D Hays; R Harooni; L W Myers; G W Ellison
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

9.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

10.  Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group.

Authors:  S A Shumaker; J F Wyman; J S Uebersax; D McClish; J A Fantl
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

View more
  5 in total

1.  Quality of life of neurogenic patients: translation and validation of the Portuguese version of Qualiveen.

Authors:  Carlos Arturo Levi D'Ancona; José Tadeu Tamanini; Neury Botega; Nivaldo Lavoura; Ruiter Ferreira; Victor Leitão; Maria Helena Baena M Lopes
Journal:  Int Urol Nephrol       Date:  2008-06-05       Impact factor: 2.370

2.  Bladder-related quality of life in people with neurological disorders: reliability and validity of the Turkish version of the King's Health Questionnaire in people with spinal cord injury.

Authors:  Hale Karapolat; Yeşim Akkoç; Sibel Eyigör; Göksel Tanıgör
Journal:  Turk J Urol       Date:  2018-03-09

Review 3.  Recommendations for evaluation of neurogenic bladder and bowel dysfunction after spinal cord injury and/or disease.

Authors:  Denise G Tate; Tracey Wheeler; Giulia I Lane; Martin Forchheimer; Kim D Anderson; Fin Biering-Sorensen; Anne P Cameron; Bruno Gallo Santacruz; Lyn B Jakeman; Michael J Kennelly; Steve Kirshblum; Andrei Krassioukov; Klaus Krogh; M J Mulcahey; Vanessa K Noonan; Gianna M Rodriguez; Ann M Spungen; David Tulsky; Marcel W Post
Journal:  J Spinal Cord Med       Date:  2020-03       Impact factor: 1.985

Review 4.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

5.  [Quality of life in German-speaking patients with spinal cord injuries and bladder dysfunctions. Validation of the German version of the Qualiveen questionnaire].

Authors:  J Pannek; R Märk; M Stöhrer; B Schurch
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.